September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
A clinical survey on subcutaneous triamcinolone acetonide eyelid injection for vernal keratoconjunctivitis.
Author Affiliations & Notes
  • Tomoko Kawamura-Tsukahara
    ophthalmology, Fukuoka University, Fukuoka, Japan
  • YUSUKE SAEKI
    ophthalmology, Fukuoka University, Fukuoka, Japan
  • Jane Huang
    ophthalmology, Fukuoka University, Fukuoka, Japan
  • Eiichi Uchio
    ophthalmology, Fukuoka University, Fukuoka, Japan
  • Footnotes
    Commercial Relationships   Tomoko Kawamura-Tsukahara, None; YUSUKE SAEKI, None; Jane Huang, None; Eiichi Uchio, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3500. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Tomoko Kawamura-Tsukahara, YUSUKE SAEKI, Jane Huang, Eiichi Uchio; A clinical survey on subcutaneous triamcinolone acetonide eyelid injection for vernal keratoconjunctivitis.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3500.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report the results of our clinical survey on subcutaneous triamcinolone acetonide eyelid (STAE) injection for vernal keratoconjunctivitis (VKC).

Methods : Fifteen VKC patients were recruited for the clinical survey on STAE injections in Fukuoka University Hospital. All had past histories of single or multiple STAE injections. It was a closed question survey with yes or no answers. Survey was responded by either the patients themselves or by the guardian when the patient had not reached a reading age. Survey included questions on how the patient felt during the STAE injection, how symptoms have changed after the injection, any symptoms of side effects, and if the patient would want another STAE injection when symptoms recurred.

Results : Average age of initial STAE injection was 11.4 years old (5-24 years old). Fourteen male and one female were included. Average repeated injections were 4.1 times(1-10 times). Ten out of 15 were frightened during the injection, 14 out of 15 felt immediate relief in eye symptoms, 9 out of 15 had no signs of any side effects, and 11 out of 15 would do repetitive STAE injections when symptoms recurred. Average age of initial injection of three cases denied STAE injections was 7.33 years old, and this group was significantly younger than the group which wants to receive STAE injections (t test, p=0.023).

Conclusions : Our clinical survey provided insights into the changing of adjunctive VKC treatment with STAE injection. Survey revealed an immediate relief of symptoms after the injection and despite of being frightened during the procedure, most of the patients were willing to go through the procedure again when symptoms recurred.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×